New blood treatment aims to make transfusions safer

NCT ID NCT07015437

Recruiting now Knowledge-focused Sponsor: Cerus Corporation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a device called the INTERCEPT Blood System that treats red blood cells to kill germs. Researchers want to see if treated red blood cells survive as well as untreated ones after 35 days of storage. About 70 healthy adults will donate blood, have it treated or not, and then get a small amount back to measure how long the cells last. The goal is to ensure the treated blood is safe and effective for future transfusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INTERCEPT Blood System for RBCs (device) and radiolabeled autologous red blood cells
What this could lead to: If successful, this could show that INTERCEPT-treated red blood cells are safe and viable for transfusion, potentially reducing infection risks in blood transfusions.
What could go wrong: This is an early phase 2 study in healthy volunteers, not patients. The treatment may not perform as well as standard RBCs, and results may not translate to real-world transfusion settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY SUBJECTS

Contacts and locations

Locations

American Red Cross Research Laboratory
RECRUITING

Norfolk, Virginia, 23510, United States
Hoxworth Blood Center
NOT_YET_RECRUITING

Cincinnati, Ohio, 45267, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.